Related Experiment Video
Updated: May 22, 2025

A Protocol for the Production of KLRG1 Tetramer
Published on: January 12, 2010
Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop
Nadine Soudah1, Alexey Baskin1, Merav Darash-Yahana1
1Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Abstract:
The receptor tyrosine kinase (RTK)-Ras-Raf-MEK-Erk cascade is frequently mutated in cancer, but it is not known whether Erk is a sole mediator of the pathway's oncogenicity, and what degree of Erk activity is required for oncogenicity. Also, it is assumed that high Erk activity is required to impose and maintain oncogenicity, but the exact degree of required activity is not clear. We report that induced expression of the intrinsically active variant Erk1R84H in mouse liver gave rise to hepatocellular carcinoma (HCC). Intriguingly, the phosphorylated/active form of Erk1R84H was dramatically downregulated during HCC development, and became almost undetectable in mature tumors. Similarly, in Erk1R84H-transformed NIH3T3 cells, the phosphorylated/active form of Erk1R84H was undetectable. Thus, 1) Erk1 could by itself cause HCC in mice, suggesting that it is the major or even the sole mediator of the cascade's oncogenicity. 2) Erk1R84H-induced tumors (and other tumors) are maintained by a minimal Erk activity. 3) Erk1R84H is probably the driver of the malignancy in patients that carry the R84H mutation.
Insights
The engineered Erk1 protein can cause liver cancer in mice, indicating it may be the primary driver of this pathway
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- The receptor tyrosine kinase (RTK)-Ras-Raf-MEK-Erk pathway is frequently altered in various cancers.
- The precise role and required activity level of Erk in mediating oncogenicity remain unclear.
Purpose of the Study:
- To investigate if Erk is the sole mediator of the RTK-Ras-Raf-MEK-Erk pathway's oncogenic potential.
- To determine the degree of Erk activity necessary for oncogenicity.
Main Methods:
- Induced expression of an intrinsically active Erk1 variant (Erk1R84H) in mouse liver.
- Analysis of Erk1R84H phosphorylation levels during hepatocellular carcinoma (HCC) development.
- Examination of Erk1R84H-transformed NIH3T3 cells.
Main Results:
- Induced Erk1R84H expression in mouse liver led to hepatocellular carcinoma (HCC).
- Active phosphorylated Erk1R84H levels decreased significantly during HCC progression and were undetectable in mature tumors.
- Phosphorylated Erk1R84H was also undetectable in Erk1R84H-transformed NIH3T3 cells.
Conclusions:
- Erk1 can independently induce HCC, suggesting it's a major or sole oncogenic mediator in its pathway.
- Tumor maintenance driven by Erk1R84H requires only minimal Erk activity.
- The Erk1R84H mutation is likely a driver of malignancy in human cancers.
Related Concept Videos
Regulation of the Unfolded Protein Response
Non-LTR Retrotransposons
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
MAPK Signaling Cascades

